Role of endothelial microRNA 155 on capillary leakage in systemic inflammation

Etzrodt, Valerie ; Idowu, Temitayo O ; Schenk, Heiko ; Seeliger, Benjamin ; Prasse, Antje ; Thamm, Kristina ; Pape, Thorben ; Müller-Deile, Janina ; van Meurs, Matijs ; Thum, Thomas ; Garg, Ankita ; Geffers, Robert ; Stahl, Klaus ; Parikh, Samir M ; Haller, Hermann ; David, Sascha

Abstract: BACKGROUND Capillary leakage is a key contributor to the pathological host response to infections. The underlying mechanisms remain incompletely understood, and the role of microRNAs (MIR) has not been investigated in detail. We hypothesized that specific MIRs might be regulated directly in the endothelium thereby contributing to vascular leakage. METHODS SmallRNA sequencing of endotoxemic murine pulmonary endothelial cells (ECs) was done to detect regulated vascular MIRs. In vivo models: transgenic zebrafish (flk1:mCherry/l-fabp:eGFP-DPB), knockout/wildtype mouse (B6.Cg-Mir155tm1.1Rsky/J); disease models: LPS 17.5 mg/kgBW and cecal ligation and puncture (CLP); in vitro models: stimulated human umbilical vein EC (HUVECs), transendothelial electrical resistance. RESULTS Endothelial MIR155 was identified as a promising candidate in endotoxemic murine pulmonary ECs (25 × upregulation). Experimental overexpression in a transgenic zebrafish line and in HUVECs was sufficient to induce spontaneous vascular leakage. To the contrary, genetic MIR155 reduction protects against permeability both in vitro and in endotoxia in vivo in MIR155 heterozygote knockout mice thereby improving survival by 40%. A tight junction protein, Claudin-1, was down-regulated both in endotoxia and by experimental MIR155 overexpression. Translationally, MIR155 was detectable at high levels in bronchoalveolar fluid of patients with ARDS compared to healthy human subjects. CONCLUSIONS We found that MIR155 is upregulated in the endothelium in mouse and men as part of a systemic inflammatory response and might contribute to the pathophysiology of vascular leakage in a Claudin-1-dependent manner. Future studies have to clarify whether MIR155 could be a potential therapeutic target.

DOI: https://doi.org/10.1186/s13054-021-03500-0
Etzrodt, Valerie; Idowu, Temitayo O; Schenk, Heiko; Seeliger, Benjamin; Prasse, Antje; Thamm, Kristina; Pape, Thorben; Müller-Deile, Janina; van Meurs, Matijs; Thum, Thomas; Garg, Ankita; Geffers, Robert; Stahl, Klaus; Parikh, Samir M; Haller, Hermann; David, Sascha (2021). Role of endothelial microRNA 155 on capillary leakage in systemic inflammation. Critical Care, 25:76.
DOI: https://doi.org/10.1186/s13054-021-03500-0
Role of endothelial microRNA 155 on capillary leakage in systemic inflammation

Valerie Etzrodt1†, Temitayo O. Idowu1†, Heiko Schenk1,9, Benjamin Seeliger2, Antje Prasse2, Kristina Thamm1, Thorben Pape1, Janina Müller-Deile3, Matijs van Meurs4, Thomas Thum5, Ankita Garg3, Robert Geffers6, Klaus Stahl7, Samir M. Parikh8, Hermann Haller1,9 and Sascha David1,10*

Abstract

Background: Capillary leakage is a key contributor to the pathological host response to infections. The underlying mechanisms remain incompletely understood, and the role of microRNAs (MIR) has not been investigated in detail. We hypothesized that specific MIRs might be regulated directly in the endothelium thereby contributing to vascular leakage.

Methods: SmallRNA sequencing of endotoxemic murine pulmonary endothelial cells (ECs) was done to detect regulated vascular MIRs. In vivo models: transgenic zebrafish (flk1:mCherry/l-fabp:eGFP-DPB), knockout/wildtype mouse (B6.Cg-Mir155tm1.1Rsky/J); disease models: LPS 17.5 mg/kgBW and cecal ligation and puncture (CLP); in vitro models: stimulated human umbilical vein EC (HUVECs), transendothelial electrical resistance.

Results: Endothelial MIR155 was identified as a promising candidate in endotoxemic murine pulmonary ECs (25 × upregulation). Experimental overexpression in a transgenic zebrafish line and in HUVECs was sufficient to induce spontaneous vascular leakage. To the contrary, genetic MIR155 reduction protects against permeability both in vitro and in endotoxia in vivo in MIR155 heterozygote knockout mice thereby improving survival by 40%. A tight junction protein, Claudin-1, was down-regulated both in endotoxia and by experimental MIR155 overexpression. Translationally, MIR155 was detectable at high levels in bronchoalveolar fluid of patients with ARDS compared to healthy human subjects.

Conclusions: We found that MIR155 is upregulated in the endothelium in mouse and men as part of a systemic inflammatory response and might contribute to the pathophysiology of vascular leakage in a Claudin-1-dependent manner. Future studies have to clarify whether MIR155 could be a potential therapeutic target.

Keywords: Tight junctions, Respiratory distress syndrome, MicroRNAs, Endothelium, Sepsis

Background

Sepsis is defined as a life-threatening pathological host response to infection [1]. Key components of this host response are (1) a dysfunctional (often overwhelming) immune reaction, (2) intravascular coagulopathy and (3) global endothelial dysfunction all together leading to a microvascular stasis, organ hypo-perfusion and ultimately fatal multi-organ failure. The mortality ranges between 32 and 56% [1, 2]. A deleterious vascular mal-adaptation can occur in virtually all syndromes that are characterized by a systemic inflammatory response both in septic and aseptic conditions (e.g., pancreatitis, burns, post-cardiopulmonary bypass) [3]. The underlying molecular mechanisms have been investigated for some time but are still incompletely understood. The molecular
basis for maintenance of cell–cell contacts is the so-called adherens and tight junctions, transmembrane proteins that dynamically link adjacent cells to one another [4]. These junctions consist of a variety of proteins that are connected and form a robust scaffold with the intracellular actin cytoskeleton. Targeting one component of these complicated structures might have catastrophic effects on the stability of the whole complex. Some of these junctional proteins have been demonstrated to be altered in expression, structure and/or localization in systemic inflammation (e.g., VE-cadherin, catenins, Claudin-1 [5]).

MicroRNAs (MIR)—small non-coding RNAs that have the ability to simultaneously regulate a variety of proteins—have not been investigated in detail in modulating the endothelial junctional apparatus thus controlling permeability [6]. In this context, one could hypothesize, that MIRs could trigger mechanisms that affect endothelial barrier function by targeting both essential proteins of the junctional apparatus or of the cytoskeleton either in a beneficial or harmful nature.

We hypothesized that specific MIRs might be up-/or down-regulated in systemic inflamed endothelium thereby contributing to the degradation of critical components of endothelial junctions or cytoskeletal components. To analyze this, we first performed an unbiased MIR analysis using a small RNA sequencing strategy from endotoxemic murine pulmonary endothelial cells and identified MIR155 as a potential candidate of interest. We then analyzed endothelial MIR155 regulation in systemic inflammation in transgenic zebrafish, wildtype and knockout mice, human endothelial cells, septic systemic inflammation in transgenic zebrafish, wildtype and knockout mice, human endothelial cells, septic human kidney biopsies, and in bronchoalveolar lavage fluid (BALf) and serum samples from ARDS patients.

Material and methods
We followed the ARRIVE guidelines (www.arriveguidelines.org) throughout the investigation whenever applicable.

Antibodies and reagents
All chemical and reagents, unless otherwise specified, were purchased from Sigma-Aldrich. Antibodies against Claudin-1, ZO-1, GAPDH and Alexa Fluor 546 Phalloidin, 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Hilden, Germany) and Aquapoly/Mount were used.

miRNA analysis using smallRNA-Seq
RNA sequencing library was generated from 0.1 to 1 µg of total RNA using TruSeq® Small RNA Library Prep Kits v2 (Illumina) according to manufacturer’s protocols. The libraries were sequenced on Illumina HiSeq2500 using TruSeq SBS Kit v3-HS (50 cycles, single ended run) with an average of 10 × 106 reads per RNA sample. FASTQ files were trimmed with fastq-mcf (ea-utils, https://expressionanalysis.github.io/ea-utils/) removing Illumina RNA adapter sequences (TGGAATTCTCGGGTGCCAGG) and nucleotides with phred scores below 20. [7–10]

Cell culture studies
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical veins (donor approval, Hannover Medical School Nr. 1303-2012). Specific miRCURY LNA miRNA mimic (No. 339173) (Qiagen, Hilden, Germany) was used to overexpress the microRNA 155. To inhibit the microRNA 155, the miRCURY LNA miRNA Inhibitor 5 nM was used (No. 339121) (Qiagen, Hilden, Germany).

Mouse studies
All mouse experiments were approved by the local authorities at Hannover Medical School and conducted in accordance with institutional and governmental guidelines (LAVES Lower Saxony, Ref. No. 18/2817). Male B6.Cg-Mir155tm1.1Rsky/J were used as MIR155 knockout mouse. The mice, 10–12 weeks of age, were either injected intraperitoneally (i.p.) with 17.5 mg/kg body-weight lipopolysaccharide (LPS) or a cecal ligation puncture (CLP) as described elsewhere [11] was conducted. Briefly, the LPS originated from Escherichia coli, serotype O111:B4 (Sigma-Aldrich, St. Louis, MO) dissolved in 10 mL/kg sterile NaCl. The injected mice were monitored and scored according to Additional file 1: Table S4. After 16 h, they were killed and organs harvested. For the performance of the CLP experiment, the mice were anaesthetized with isoflurane (1–2% in medical air) and a midline laparotomy was placed by a single-blinded operator. The anti-mesenteric border was ligated, and through one single 20G needle puncture 1 mm of stool was extracted. As a sham surgery, laparotomy with cecal mobilization was performed. Followed by the two-layering closure, mice were given 200 µL of NaCl fluids s.c. and for analgesia once 10 mg/mL Butorphanol (Zoetis Manufacturing & Research, Spain). Until the organ harvest 24 h later, the mice were monitored and scored by a single-blinded investigator. The Evans Blue permeability assay (EB) was conducted as described [11]. In brief, the mice were injected with the 100 µL of 2% wt/vol EB in the tail vein 12 h after LPS injection. For lung cufing, mice were challenged with LPS (17.5 mg/kg BW) and killed 16 h later and organs were harvested. After the staining process, a lung cufing score and a percentage of cufing (yes / no) were raised by a single-blinded person (see Additional file 1: figure S1 and table S2). For Kaplan–Meier survival studies, both models, i.e., LPS and CLP were used. All experiments were performed and analyzed by a blinded investigator.
Western blot analysis

The Western Blot Analysis was conducted as in [12] described using the SuperSignal™ West Pico Chemiluminescent Substrate (Life Technologies) and Versa Doc Imaging System Model 3000 (BioRad, Hercules, CA) was used to visualize the bands.

Fluorescent immunocyto-/histochemistry

HUVECs were grown to confluency on Collagen (Sigma-Aldrich, St.Louis, MO) covered coverslips. Antibodies and reagents were used as described above.

Paraffin slices were deparaffinned and blocked with 10% donkey serum (Jackson Immuno Research Inc., West Grove, PA). GR-1 was used as primary antibody and pictured with the secondary antibody (goat anti-rat IgG (Alexa flour 555)) (Invitrogen, CA). To evaluate the amount of lung cuffing through scores, mice lungs were stained with Periodic Acid Schiff (PAS) Staining and scored according to Additional file 1: Table S2. The images were taken with the Leica DMI 6000B microscope under the same gain and offset conditions.

(Micro) RNA isolation and quantitative (q) PCR

For the isolation, the miRNeasy Mini Kit was used (Qiagen, Hilden, Germany) to extract both miRNA and RNA from HUVECs and organ tissue followed by Prime Script RT Reagent Kit (TaKaRa Bio Europe SAS, St Germain-en-Laye, France) after the manufacturer’s instructions.

Immunoprecipitation of MIR155

HUVECs were plated at 1.8 × 105 cells/well in 6 well-plate overnight and transfected with 200 pM biotinylated control miRNA mimics or 5'-Biotinylated MIR-155 mimics (No. 339178) (Qiagen, Hilden, Germany) using HiPerfect (Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions. After 48 h of transfection, cells were harvested in 700 μL lysis buffer supplemented with Protease Inhibitor Cocktail (Roche, South San Francisco, CA) and RNaseOUT (Invitrogen) and incubated on ice for 20 min. Lysates were centrifuged at 10,000 × g for 15 min at 4 °C after which 50 μl of the cytoplasmic lysate (input) was transferred into a new tube for RNA extraction. The remaining supernatant was incubated with activated Streptavidin-Dynabeads (Dynabeads M-280 Streptavidin, Invitrogen) for 4 h at 4 °C. After several washing steps and centrifugation, the supernatant was taken for RNA extraction. RNA was subjected to qPCR using Claudin-1 specific primers. The analysis was done as follows: MiRNA pull-down/control pull-down (A'), miRNA input/control input ('B'); fold enrichment = A/B.

Zebrafish studies

Female Tg(flk1:mCherry) zebrafish were mated with male Tg(l-fabp:eGFP-DPB) to generate Tg(flk1:mCherry/l-fabp:eGFP-DPB) zebrafish offspring. Eggs were micro-injected with a MIR155 mimic or a scrambled MIR (mirVana, life technologies) at the one to four cell stage at a concentration of 25 μM [13]. At 96 h post-fertilization, the vascular integrity of the transgenic larvae based on flk1 expression in ECs was determined. In parallel, the plasma protein loss of eGFP-DBP was analyzed by measurement of fluorescence intensity in the retinal vessel plexus [13]. The zebrafish animal studies were performed according to the National Institutes of Health Guideline for the Care and Use of Laboratory Animals. The Mount Desert Island Biological Laboratory (Bar Harbor, ME) animal care committee approved the animal protocol (IACUC protocol #1703). The analysis was performed using ImageJ (Version 1.60, National Institutes of Health, Bethesda, MD) and reported in arbitrary units.

Transendothelial electrical resistance (TER)

TER was measured using an electric cell-substrate impedance sensing system (ECIS) (Applied BioPhysics Inc.). The continuous values were pooled at discrete time points and plotted versus time. Each conditions’ end point resistance was divided by its starting resistance to give the normalized TER [14].

Human kidney biopsies

Kidney biopsies were obtained directly post-mortem from patients aged 18 years or older, who died of sepsis. Kidneys from patients diagnosed with kidney cancer who underwent a total nephrectomy, served as controls as described in Aslan et al. Crit. Care. (2014) [15]. The postmortem biopsies were waived by the Medical Ethical Committee of the UMCG, Groningen, The Netherlands (METc 2011/372) [15].

Expression of MIR155 in human septic serum and bronchoalveolar lavage fluid (BALf) of patients with ARDS

MIR155 expression was measured in serum and BALf samples collected within 24 h of disease onset in patients with ARDS (n = 16), with clinical details provided in Table 1 and in healthy controls (n = 5). The collection of the BALf and serum samples was approved according to the ethics committee of Hannover Medical School (MHH, EK 8146_BO_K_2018). Total RNA was isolated from human BALf and serum samples using miRNeasy Serum/Plasma Advanced Kit (Qiagen, Cat. No. 217204) following manufacturer’s instructions. For the BALf analysis, we established a novel method base on the above...
Table 1 Clinical features of acute respiratory distress syndrome (ARDS) patients

| Characteristic                        | All (n = 16) |
|---------------------------------------|--------------|
| Age (y), median (IQR)                 | 52 (43–66)   |
| Male (%)                              | 12 (75)      |
| Body mass index (kg/m²), median (IQR) | 27.7 (24.4–33.3) |
| Septic shock (%)                      | 9 (56)       |
| Pneumonia due to                      | 14 (88)      |

Laboratory at time of sampling

| CRP (mg/L), median (IQR)   | 252 (134–305) |
| Procalcitonin (ng/L), median (IQR) | 7.7 (1.4–29.1) |
| Leukocytes (gpt/L), median (IQR) | 8.2 (4.8–19.1) |
| Lactate (mmol/L), median (IQR) | 1.6 (1.2–3.2) |
| pO₂/FiO₂ (mmHg), median (IQR) | 109 (77–132)  |
| SOFA score at day of sampling (IQR) | 11.5 (8.5–13.0) |

Treatment modalities at time of sampling

| Invasive ventilation | 16 (100) |
| PEEP (mbar), median (IQR) | 14 (12–15) |
| Pmax (mbar), median (IQR)  | 26 (23–28) |
| Extracorporeal membrane oxygenation (%) | 7 (44) |
| Renal replacement therapy (%) | 10 (63) |
| Vasopressor use (%)       | 13 (81)   |
| Noradrenaline dose (µg/kg/min), median (IQR) | 0.085 (0.02–0.35) |
| 28-day ICU-mortality (%) | 5 (31)   |

ARS syndrome (ARDS) patients, CRP C-reactive protein, IQR interquartile range, pO₂ arterial partial pressure of oxygen, PEEP positive end expiratory pressure, SOFA score sequential organ failure assessment score. MIR155 expression in relation to cel-MIR39 was lowest in healthy controls (1.03 ± 0.12) versus ARDS patients (12.23 ± 3.0)

kit used for the serum. Cel_MIR-39 miRNA mimic (Qiagen, Cat. No. 219610) at a concentration of 1.6 × 108 copies/µL was used as a spike-in miRNA control. The reverse transcription for miRNAs was done with equal volume of starting total RNA for each sample and specific TaqMan probes (Applied Biosystems; for MIR-155: Assay ID 002623 and for Cel_MIR-39: Assay ID 000200) using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Cat. No. 4366597) as per the manufacturer’s guidelines. Viia7 system (Applied Biosystems) was used to perform miRNAs’ quantification PCR (qPCR) with MIR-155 or Cel_MIR-39 specific TaqMan assays (Applied Biosystems) and Absolute Blue qPCR Mix (Abgene, Cat. No. AB-4136/B). The collection of the BALf and serum samples was approved according to the ethics committee of Hannover Medical School (MHH, EK 8146_BO_K_2018).

Statistical analysis

Statistical significance was evaluated using Mann–Whitney test or one-way ANOVA unless otherwise noted. All experimental results are presented as mean ± SD, and a two-tailed p value of less than 0.05 was considered to indicate statistical significance. GraphPad Prism 6.0 (La Jolla, CA).

Results

Identification of MIRs that are regulated in the endothelium in systemic inflammation

Mice were challenged intraperitoneally with a high dosage of LPS (17.5 mg/kg bodyweight, n = 3) or vehicle (n = 3) to induce a systemic inflammatory response that regularly leads to severe pulmonary capillary leakage. Mice were killed after 24 h, and lungs were harvested for endothelial cell (EC) separation with a magnetic CD146 antibody strategy followed by isolation of MIRs. SmallRNA sequencing was performed together with the Helmholtz Institute (Brunswick, Germany). A heatmap of regulated MIRs of the 6 included animals is shown in Fig. 1a and Additional file 1: Table S1. In summary, out of 318 investigated MIRs, 5 were down- and 31 up-regulated (Fig. 1b and Additional file 1: Table S2). Of note, MIR155—that had not been studied in the septic endothelium so far—showed the strongest signal in our analysis and was therefore followed-up on in the next experiments.

To confirm these earlier findings of the smallRNA seq, MIR155 was first quantified by RT-PCR from whole lung lysates in endotoxemic and control mice at different time-points. Already after 4 h, we found a 6 × fold increase in the LPS-treated mice (Fig. 1c, p < 0.01). Given that MIR155 is also expressed by other cells types (e.g., epithelial and immune cells), we selected specifically CD146⁺ pulmonary ECs, which showed an even larger upregulation (i.e., 8 × fold MIR155 increase, Fig. 1d, p < 0.01). To confirm these results in a cellular context and to set a system for further mechanistic in vitro studies, confluent HUVEC monolayers were stimulated with 50 ng/mL TNFα (a key cytokine of systemic inflammation) and harvested in a time-dependent fashion. Indeed, TNFα challenge of ECs was sufficient to induce a significant upregulation of the MIR155 already after 2 h (p < 0.01) with a maximum response exceeding 15 × fold after 24 h (p < 0.001, Fig. 1e).
Functional consequences of MIR155 overexpression and inhibition in vivo

Given the lack of knowledge on the functional role of MIR155 in the endothelium, we investigated it in a transgenic Tg(flk1:mCherry)/Tg(l-fabp:eGFP-DBP) zebrafish line. This zebrafish model allowed us (1) to rapidly overexpress MIR155 by microinjection of a MIR155 mimic and (2) to analyze vascular phenotypes. Simplified, this transgenic fish expresses a red cherry protein in the vasculature and has an enhanced green fluorescent protein bound to Vitamin D binding protein (eGFP-DBP) (corresponds to the intravascular compartment, i.e., the plasma). Both loss of GFP intensity in the retinal vessels and the development of pericardial effusion can be used as a surrogate of vascular leak [13, 16]. Indeed, overexpression of MIR155 led to a visually detectable loss of GFP in the red vascular tree and fluid accumulation in the pericardium (Fig. 2a–c). Visualization and quantification of the retinal GFP expression showed a decrease in fluorescence intensity ($p < 0.0001$) supporting the hypothesis that experimental overexpression of MIR155 is sufficient to induce vascular permeability (even in the absence of systemic inflammation) (Fig. 2d–f).
To assess the role of the MIR155 in mammals, knock-out mice and littermate wildtypes were challenged with LPS or vehicle and permeability was assessed in vivo by the Evans Blue (EB) method. Septic wildtypes showed a 2.2-fold increase in lung EB extravasation quantified by spectroscopic analysis of the grounded tissue. Interestingly, homozygote knockouts (MIR155−/−) were not protected, but the heterozygote MIR155 mice (MIR155+/−) showed barrier properties that were indistinguishable from healthy controls (Fig. 3a).

Bronchiolar cuffing is a histological method to visualize pulmonary edema (Additional file 1: Fig. S1). Again, septic wildtype mice showed a severe cuffing phenotype (Fig. 3b, second panel) that was less severe in the heterozygote context (third panel) but not different in the MIR155−/− mice (fourth panel). This finding was semi-quantified by a blinded investigator both with regard to the percentage of cuffing positive bronchi (Fig. 3c) and the severity of cuffing (Fig. 3d). In addition to these observations with regards to permeability, we found additional evidence that the endothelial inflammatory response might be positively influenced if MIR155 is experimentally reduced (Additional file 1: Fig. S2). Together these findings support that MIR155 upregulation in systemic inflammation might be an injurious contributor to vascular leakage across different species.

**Functional consequences of MIR155 overexpression and inhibition in vitro**

In vitro, naïve or MIR155 modulated HUVECs were challenged with thrombin (a mediator of systemic inflammation and an established inductor of EC permeability in vitro) to recapitulate the above described in vivo findings. Thrombin stimulation primed the formation of F-actin polymerization and gap formation between adjacent ECs leading to an increase in permeability (white arrows) (Fig. 4a, lower left). ECs that have been challenged with a MIR mimic (w/o thrombin) partly phenocopied these permeability patterns (Fig. 4a, upper right). Interestingly, from a therapeutic point of view, ECs that have been co-stimulated with thrombin + anti-MIR155 peptide were protected from the development of the before described endothelial morphological changes (Fig. 4a, lower middle panel). To reliably quantify these qualitative changes in morphology, we measured TER in real-time with Electric Cell-substrate Impedance Sensing (ECIS). MIR155 overexpression was not sufficient...
to induce leak in this assay by itself, but MIR155 overexpression critically interfered with the usual recovery after stimulation with thrombin (Fig. 4b). More important from a translational aspect, inhibition of MIR155 (anti-MIR155) was sufficient to reduce the deleterious effect of thrombin in this highly sensitive assay (Fig. 4c, p < 0.05). Together these findings support our hypothesis that upregulation of MIR155 in the septic endothelium is indeed injurious and that its inhibition might represent a therapeutic target.

Identification of MIR155 target candidates

Using an in silico analysis tool (http://www.targetscan.org), we identified 556 potential transcripts with preserved sites among various species that might be influenced by MIR155. Given the permeability phenotype in our in vivo and in vitro models, we specifically looked at proteins involved in the junctional apparatus. The analysis predicted that Claudin-1 could be a possible target that additionally showed conserved binding sites among different species (e.g., human, cow, rat, mouse, dog). First, we checked if Claudin-1 expression is indeed altered in LPS-treated mice and found a significant reduction in their lungs (Fig. 4d). Experimental up-regulation of MIR155 in ECs in vitro to a similar extent that we earlier detected in systemic inflamed mice (Additional file 1: Fig. S3) induced a significant downregulation of Claudin-1 on mRNA and protein levels (Fig. 4e, f). Using an immunoprecipitation strategy from ECs stimulated with an MIR155 mimetic, we could confirm the physical binding of MIR155 with claudin-1 (Fig. 4g). However, inhibition of MIR155 was not sufficient to increase Claudin-1 expression spontaneously (data not shown).

Effect of MIR155 depletion on clinical outcomes in murine sepsis

Next, we tested if the previously observed attenuation of permeability in the MIR155 heterozygote mice might be sufficient to protect from organ dysfunction and death. Analysis of functional organ parameters from serum samples 24 h after LPS administration in all genotypes showed trends towards improved organ function and survival in a 100% lethal model (Additional file 1: Table S3 and Fig. S3.) in the heterozygous MIR155+/− mice (median survival MIR155+/− 25.5 h vs MIR155++/− 36 h). The 100% lethality of our endotoxemia model combined with increasing doubts regarding the clinical relevance of this model in the sepsis community [17] inspired us to test outcome in a clinically more meaningful polymicrobial sepsis model, i.e., CLP. Upon CLP surgery,
Fig. 4  Functional effects of MIR155 on permeability and target candidates. a) Control, Anti-MIR155 and MIR155<sub>high</sub> human umbilical vein endothelial cells (HUVECs) were challenged with thrombin or vehicle following staining with a tight-junction protein (ZO-1, green), the cytoskeleton (F-actin, red) and DAPI (blue). Thrombin challenged ECs showed visible gap formation between adjacent cells (white arrows). Blockade of MIR155 had visually lesser gap formations upon thrombin stimulation (lower middle panel). Whereas the MIR155<sub>high</sub> transfected HUVECs showed mild spontaneous (upper right) and severe gap formation after thrombin stimulation (lower right). b) MIR155 transfected HUVECS (MIR155<sub>high</sub>) were grown under constant detection of the transendothelial resistance (TER) until confluency was reached. Challenge with thrombin showed a stronger decrease and slower recovery (endpoint p < 0.05) in MIR155<sub>high</sub> compared to naïve ECs. c) Continuous TER between vehicle and Anti-MIR155 challenged with thrombin showed an amelioration of maximal response and faster re-bound recovery than the corresponding control group (deepest drop point p < 0.05). d) Densitometry from C57BL/6J mouse lungs challenged with either LPS (17.5 mg/kg BW, n = 5) or vehicle (NaCl 0.9%, n = 7). After 16 h they were killed and Claudin-1 (CLDN-1) and b-Actin were detected by immunoblotting (p < 0.05). e) Bar graphs showing normalized mRNA of Claudin-1/bActin in MIR155<sub>high</sub> and naïve (CTR) HUVECs (n = 6–7; p < 0.01). f) Bar graphs showing densitometry results of Claudin-1/bActin immunoblots in MIR155<sub>high</sub> versus naïve (CTR) HUVECs (n = 6–7; p < 0.01). g) Bar graphs showing immunoprecipitation of the Claudin-onefold enrichment normalized to GAPDH (n = 4, p < 0.05), after the overexpression of MIR155 in HUVECs (n = 4, p < 0.05).
mice were regularly scored for severity of disease by a single-blinded investigator using a standardized activity score (Additional file 1: Table S4). Consistent with the permeability data, MIR155+/− mice had a better physical performance indicating a less severe disease manifestation than all other groups over a 96 h observation period (Fig. 5a) and indeed showed a clear survival benefit by approximately 60% compared to the MIR155+/+ mice. (Mantel–Cox Test, p < 0.05, Fig. 5b).

**Translational evidence of MIR155 regulation in human disease**

Given the discovery of both cross-species regulation and relevance of MIR155 in increased endothelial permeability, we set out to investigate its regulation in a human organism. To do this, we followed two strategies. First, we analyzed BALf and serum from critically ill patients suffering from ARDS—a syndrome that is pathophysiologically based on increased vascular permeability. Patients characteristics are summarized in Table 1. To our surprise, circulating MIR155 levels were not different between controls and ARDS patients (Fig. 6a). Given that we identified MIR155 with the RNA seq specifically in the pulmonary endothelium, we analyzed local MIR155 abundance in the alveoli (i.e., BALf) of healthy controls and ARDS patients. The healthy volunteers (n = 5) had a median age of 26.9 years [IQR 22.5–33.1] and were all male. Consistent with our previous findings, we found a massive MIR155 upregulation in ARDS patients in this local compartment, close to the pulmonary endothelium.
MIR155 could blunt microvascular endothelial expres-
sions against barrier breakdown following
lar endothelial cells against barrier breakdown following
ified monolayers of human primary brain microvascu-
lar endothelium of endotoxemic mice. MIR155 overex-
pression was sufficient to induce spontaneous vascular
leakage in zebrafish, augment pathological responses in
cultured human endothelial cell monolayers and excer-
cate the endothelial inflammatory response in murine
sepsis. Moreover, pharmacological inhibition or genetic
depletion of MIR155 prevented breakdown of the vascu-
lar barrier and improved global outcome in animal mod-
els of systemic inflammation and sepsis. Finally, MIR155
was also detectable in diverse human samples highlight-
ing the potential translational relevance of our experi-
mental findings.

In general, the role of MIRs in endothelial response
to systemic inflammation is not well understood. To
our knowledge, only a single study has linked a panel of MIRs (including MIR155) to endothelial inflamma-
tion [18], whereas most MIR155 research has focused on T-cell biology [19, 20]. Three independent reports
support our investigation of MIR155 in the inflamed vasculature. First, Han et al. reported increased circulating
MIR155 levels in human sepsis [21]. Second, Philippides et al. implicated MIR155 in the regulation of endothelial
tight junctions after cerebral ischemia [22]. Specifically, they reported that inhibition of MIR155 fortified
monolayers of human primary brain microvascular
endothelial cells against barrier breakdown following oxygen–glucose deprivation. Studying lung microvascu-
lar ECs, Pfeiffer, et al., concluded that inhibition of
MIR155 could blunt microvascular endothelial expres-
ion of inflammatory mediators [18].

Given that our transcriptomics approach in endotox-
emic mice revealed MIR155 upregulation, we first sought
to clarify if elevated endothelial MIR155 was injurious
or adaptive. Transparency of larval zebrafish and ease of
gene transduction makes this model amenable to study-
ing vascular phenotypes. Overexpression of MIR155
indeed revealed compromised vascular integrity in two
different assays, supporting the conclusion that excess
MIR155 may be alone be injurious and may potentiate
adverse responses to the septic milieu. Next, we investi-
gated a B6.Cg-Mir155tm1.1Rsky/J knockout mouse to (1)
test whether MIR155 was required for a severe inflam-
atory response; (2) evaluate the MIR155 hypothesis in a mammalian species; and (3) explore its relevance
in models of human disease. Although endotoxemia is
not a model of sepsis per se, the consequences of sterile
cytokine storm are still of translational interest, and this
noxious stimulus is an established trigger of pulmonary
vascular hyperpermeability, a key phenotype of interest
[23, 24]. LPS strain and dose were tailored in a pilot study
to induce significant pulmonary edema early in cytokine
storm rather than to evaluate overall survival. To study
survival, we applied the murine gold standard sepsis model of CLP (that was piloted to a mortality of 75%) to
MIR155 knockouts.

The absence of a gene-dose effect—namely that heter-
zygous mice were protected, whereas null mice were
not—was unexpected. However, our group has observed
similar results in the context of Angiopoietin-2, another regulator of endothelial permeability [25]. Several
hypotheses are possible. First, there might be a subtle
developmental effect of complete gene loss that is excer-
cerbated by the stress of sepsis—in the case of Angiopoie-
tin-2, null mice have marked lymphedema from aberrant
lymphangiogenesis. Second, compensatory develop-
mental and/or physiological mechanisms may become
activated with complete gene loss. For example, compens-
satory upregulation of MIR146a could be implicated in
MIR155 knockouts [18]. However, we did not find such
an association with MIR155 gene dose (data not shown).
Therefore, future experiments will be required in order to
explore the lack of protection against sepsis exhibited by
MIR155 knockout mice.

Different compartments (lung, kidney, serum) were
analyzed in the human components of this study in order
to parse local and systemic regulation of MIR155. First,
we compared bronchoalveolar lavage (BAL) fluid and
serum samples from patients with ARDS versus healthy
controls. Although reported by others [26], we did not
observe a significant change in circulating MIR155
among ARDS patients. Yet, these very same patients
showed clear MIR155 elevation in BAL samples. While
this difference may be attributable to underlying patient
and disease characteristics, the presence of a BAL-spe-
cific difference in MIR155 concentration raises the pos-
sibility of organ-specific actions of this microRNA. The
human kidney data also suggest regional regulation of
MIR155. However, results from these post-mortem
specimens may be difficult to interpret as they repres-
ent the end stage of sepsis with multiple organ failure.
On the other hand, biopsies from failing organs in sepsis
are extremely challenging to acquire, and the biopsy
itself could be harmful with limited potential benefit to
the individual patient.
Our study has important limitations. The MIR155 knockout model was neither conditional nor organ-specific. Therefore, improvement in overall survival following CLP may be partially attributable to non-endothelial effects. The observation that heterozygosity but not complete gene deletion protects from endothelial injury requires further investigation. Finally, the underlying molecular mechanisms regulating MIR155 merit future study.

Conclusions
We found cross-species evidence in knockout mice, transgenic zebrafish, human endothelial cells and critically ill patients that MIR155 is upregulated in the endothelium during systemic inflammation. MIR155 upregulation may lead to vascular barrier breakdown by targeting the tight-junction protein Claudin-1. Conversely, inhibition of MIR155 may improve vascular integrity and overall survival, making this microRNA a putative therapeutic target for further exploration in sepsis and related indications. Future experimental studies are needed to understand the regulation of MIR155 and to elucidate its downstream effects in multiple cell types.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13054-021-03500-0.

Acknowledgements
We thank Yolaine Nicolai and Anja Stankacie for the helpful professional support and Kristian Scheer for the analysis of the serum and BALf samples. VE thanks the Hannover Biomedical Research School with the StructMed Program for their support.

Authors’ contributions
SD and VE wrote the paper and designed the experiments. SD helped to create and direct the animal and cell culture experiments. VE performed all cell culture experiments, helped with the animal experiments and organized the communication between the different laboratory groups. TOI helped with animal and cell experiments and analysis. RG performed the RNAseq and provided the statistics and figures. HS and JMD conducted the zebrafish experiments, helped with the analysis and description of the results. TP helped with the animal experiments. KT performed the pilot animal and cell cultures experiments. BS collected, ordered and put into a clinical context the BALf samples. TT and AG performed the processing and analysis of BALf samples. AP provided the laboratory probes and protocol for the analysis of the BALf samples. TT and AG performed the processing and analysis of BALf and serum samples for RNA isolation and quantification. KS performed the pilot animal and cell cultures experiments, helped with the animal experiments and proofread the manuscript. HH provided the laboratory surroundings and trouble-shot the experiments. All authors read and approved the final article.

Funding
Open Access funding enabled and organized by Projekt DEAL. SD is supported by the German Research Foundation (DA 1209/4-3) and the “Deutsches Zentrum für Lungenforschung” (DZL). HS and BS are supported by PRACTIS – Clinician Scientist Programme of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1).

Availability of data and materials
All data are stored and available upon reasonable request at the laboratory of Professor David at the Hannover Medical School, Germany.

Ethics approval and consent to participate
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical veins (donor approval, Hannover Medical School Nr. 1303-2012). All mouse experiments were approved by the local authorities at Hannover Medical School and conducted in accordance with institutional and governmental guidelines (LAVES Lower Saxony, Ref. No. 18/2817). The Mount Desert Island Biological Laboratory (Bar Harbor, ME) animal care committee approved the animal protocol for the zebrafish experiments (IACUC protocol #1703). The postmortem biopsies were waived by the Medical Ethical Committee of the UMCG, Groningen, The Netherlands (METC 2011/372) (15). The collection of the BALf and serum samples was approved according to the ethics committee of Hannover Medical School (MHH, EK 8146_BO_K_2018).

Consent for publication
Not applicable.

Competing interests
SD, VE, TOI, HS, BS, AP, KT, TP, JMD, MVM, AG, RG, KS, SMP, HH declare no conflict of interest. TT is founder and shareholder of Cardior Pharmaceuticals GmbH.

Author details
1 Division of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. 2 Department of Respiratory Medicine and German Center for Lung Research, Hannover Medical School, Hannover, Germany. 3 Division of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany. 4 Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5 Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany. 6 Helmholtz Centre for Infection Research Brunswick, Brunswick, Germany. 7 Division of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 8 Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. 9 Mount Desert Island Biological Laboratory, Bar Harbor, ME, USA. 10 Institute of Intensive Care Medicine, University Hospital Zurich, Ramistrasse 100, 8092 Zurich, Switzerland.

Received: 2 September 2020 Accepted: 10 February 2021

Published online: 22 February 2021

References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
3. Robertson CM, Coopersmith CM. The systemic inflammatory response syndrome. Microbes Infect. 2006;8:1382–9.
4. Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Investig Dermatol. 2007;127:2525–32.
5. Vermette D, Hu P, Canarie MF, Funaro M, Glover J, Pierce RW. Tight junction structure, function, and assessment in the critically ill: a systematic review. Intensive Care Med Exp. 2018;6:37.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
7. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Cited 4 Mar 2020.
8. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England). 2013;29:15–21.
9. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics (Oxford, England). 2014;30:923–30.
10. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England). 2010;26:139–40.
11. Stehr T, Thamm K, Kaufmann J, Schaepfer U, Kirsch T, Haller H, et al. Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med. 2014;42:e654–62.
12. Thamm K, Schrimpf C, Retzlaff J, Idowu TO, van Meurs M, Zijlstra JG, et al. Molecular regulation of Acute Tie2 suppression in sepsis. Crit Care Med. 2018;46:e928–36.
13. Schenk H, Müller-Deile J, Kinast M, Schiffer M. Disease modeling in genetic kidney diseases: zebrafish. Cell Tissue Res. 2017;369:127–41.
14. David S, Ghosh CC, Mukherjee A, Parikh SM. Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler Thromb Vasc Biol. 2011;31:2643–52.
15. Aslan A, Jongman RM, Moser J, Stegeman CA, van Goor H, Diepstra A, et al. The renal angiopoietin/Tie2 system in lethal human sepsis. Crit Care (London, England). 2014;18:423.
16. Hanke N, Stagg L, Schroder P, Litteral J, Fleig S, Kaufeld J, et al. “Zebrafishing” for novel genes relevant to the glomerular filtration barrier. Biomed Res Int. 2013;2013:1–12.
17. Zingarelli B, Coopersmith CM, Drechsler S, Efron P, Marshall JC, Moldawer L, et al. Part I. SHOCK. 2019;51:10–22.
18. Pfeiffer D, Roßmanith E, Lang I, Falkenhagen D, mIR-146a, mIR-146b, and mIR-155 increase expression of IL-6 and IL-8 and support HSP10 in an in vitro sepsis model. PLoS ONE. 2017;12:e0179850.
19. Hippen KL, Loschi M, Nicholls J, MacDonald KPA, Blazar BR. Effects of microRNA on regulatory T cells and implications for adoptive cellular therapy to ameliorate graft-versus-host disease. Front Immunol. 2018;9:57.
20. Benz F, Roy S, Trautwein C, Rodenburg C, Luedde T. Circulating microRNAs as biomarkers for sepsis. Int J Mol Sci. 2016;17:78.
21. Han Y, Li Y, Jiang Y. The prognostic value of plasma microRNA-155 and microRNA-146a level in severe sepsis and sepsis-induced acute lung injury patients. Clin Lab. 2016;62:2355–60.
22. Pena-Philippides JC, Gardiner AS, Caballero-Garrido E, Pan R, Zhu Y, Roitbak T. Inhibition of microRNA-155 supports endothelial tight junction integrity following oxygen-glucose deprivation. J Am Heart Assoc. 2018;7:13.
23. Wong MH, Chapin OC, Johnson MD. LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system. Am J Respir Cell Mol Biol. 2012;46:641–50.
24. Johnston C. Pulmonary cytokine and chemokine mRNA levels after inhalation of lipopolysaccharide in C57BL/6 mice. Toxcol Sci. 1998;46:300–7.
25. David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, Wenger JB, et al. Angiopoetin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med. 2012;40:303–41.
26. Tacke F, Spehlmann ME, Vucur M, Benz F, Luedde M, Cardenas DV, et al. mir-155 predicts long-term mortality in critically ill patients younger than 65 years. Mediators Inflamm. 2019;2019:6714080.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.